Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).

被引：0
|
作者：
Keating, Anne Therese
Papadopoulos, Kyriakos P.
Hloros, Eleni
Spira, Alexander I.
McKean, William Bennion
Krivoshik, Andrew Peter
机构：
[1] Frontier Med, Boston, MA USA
[2] START San Antonio, San Antonio, TX USA
[3] NEXT Oncol Virginia, Fairfax, VA USA
[4] START Mt Region, West Valley City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3184
引用
收藏
页数：1
相关论文
共 50 条
  • [41] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
    Solomon, Benjamin
    Heist, Rebecca S.
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Dooms, Christophe
    Van Cutsem, Eric
    Steuer, Conor E.
    Steeghs, Neeltje
    Schuler, Martin
    Gazzah, Anas
    Wermke, Martin
    Felip, Enriqueta
    Loong, Herbert H. F.
    Luken, Maria J. De Miguel
    Soo, Ross A.
    Jaeger, Ashley
    Xu, Kun
    Chen, Xueying
    Cui, Xiaoming
    Burks, Heather
    Farago, Anna F.
    Shimizu, Toshio
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [42] Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naive and previously treated metastatic colorectal cancer (CodeBreaK 101)
    Masuishi, T.
    Kuboki, Y.
    Fakih, M. G.
    Strickler, J. H.
    Furqan, M.
    Kim, E. J.
    Cardona, P.
    Tran, Q.
    Chan, E.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S737 - S738
  • [43] A phase 1 study of tamnorzatinib (ONO-7475), an Axl/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors
    Katsuya, Yuki
    Yonemori, Kan
    Shimizu, Toshio
    Koyama, Takafumi
    Kitano, Sigehisa
    Sudo, Kazuki
    Kondo, Shunsuke
    Sato, Jun
    Hozumi, Hiroaki
    Yamamoto, Noboru
    CANCER RESEARCH, 2024, 84 (07)
  • [44] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [45] Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator's choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300)
    Paez, D.
    Meriggi, F.
    Cremolini, C.
    Folprecht, G.
    Korantzis, I.
    Chan, E.
    Tran, Q.
    Fakih, M. G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S734
  • [46] Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma
    McKean, Meredith
    Aggen, David Henry
    Lakhani, Nehal J.
    Bashir, Babar
    Luke, Jason J.
    Hoffman-Censits, Jean H.
    Alhalabi, Omar
    Bowman, Isaac Alex
    Guancial, Elizabeth A.
    Tan, Alan
    Lingaraj, Trupti
    Timothy, Marissa
    Kacena, Katherine
    Malek, Karim S.
    Santillana, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
    Patil, Tejas
    Carrizosa, Daniel R.
    Burkard, Mark E.
    Reckamp, Karen L.
    Desai, Jayesh
    Chae, Young Kwang
    Liu, Stephen V.
    Konduri, Kartik
    Gadgeel, Shirish M.
    Lin, Jessica J.
    Cheema, Parneet K.
    Spigel, David R.
    Schram, Alison M.
    Jansen, Valerie M.
    Elamin, Yasir Y.
    CANCER RESEARCH, 2023, 83 (08)
  • [48] A Phase 1/2a Study of a PI3Kδγ. dual inhibitor ZX-101A in patients with advanced solid tumors
    Qin, Xiaoli
    Luo, Lori
    Li, Ying-ying
    Wang, Yin
    Sun, Shuaijun
    Hao, Xiaolin
    Yang, Jinfu
    CANCER RESEARCH, 2022, 82 (12)
  • [49] Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
    Hong, D. S.
    Papadopoulos, K.
    Kim, D. W.
    Parikh, A.
    Barve, M.
    Powderly, J.
    Starodub, A.
    Strickler, J.
    Li, B. T.
    Oberstein, P.
    Yu, W.
    Bitman, B.
    Lally, S.
    Lin, W.
    Sohoni, S.
    Spira, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S177 - S178
  • [50] NURSING EXPERIENCE WITH PATIENTS RECEIVING SOTORASIB FOR KRAS G12C-MUTATED SOLID TUMORS: FOLLOW-UP FROM THE PHASE 1/2 CODEBREAK 100 STUDY
    Dozier, Askia
    Fitzpatrick, Victoria
    Liu, Dazhi
    Hull, Jennifer
    Varrieur, Tracy
    McGuire, Lauren
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 22 - 23
12345